METHODS

Synthesis of VCC234718
The four-step synthesis of VCC234718 (IV) was carried out as follows. 
N-(5-Isoquinolinylsulfonyl)-N'-cyclohexanoyl-piperazine (IV)
0.2 g (III) and 140 µl cyclohexanecarbonylchloride were added to the heterogeneous mixture of 15 mL ethyl acetate and 15 mL saturated bicarbonate solution with vigorous stirring. After 12 h the phases were separated, the organic phase was washed with brine, dried on sodium sulfate, and then evaporated to dryness. The crude product was purified on silica column 
ADMET
Determination of the intrinsic clearance for VCC234718 using human hepatocytes: contribution of CYP3A4
The objectives of this study were to determine the in vitro metabolic hepatic intrinsic clearance and the contribution of CYP3A to the in vitro metabolic intrinsic clearance of VCC234718 using cryopreserved human hepatocytes in primary culture.
Incubation and experimental conditions with two lots of cryopreserved human hepatocytes (purchased from Celsis/In Vitro Technologies and KaLy-Cell) were as follows:
cryopreserved hepatocytes 16 x 10 4 cells/well, collagen coated 48-well plates, incubation volume 100 µL; incubation medium, serum-free hepatocyte culture medium; VCC234718 concentration, 5 µM; sampling times, 0, 1, 2, 3, 4, 6 and 24 hours. Ketoconazole at a final concentration of 3 µM was used for the specific and potent inhibition of enzyme reactions catalyzed by CYP3A4. Quantification of VCC234718 in pooled supernatant and cells was performed using an electrospray UPLC-MS/MS method after the protein precipitation step.
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The intrinsic clearance value was calculated according to the following equation: Clint in vitro = ke . V (where Clint in vitro, is the in vitro intrinsic clearance expressed in mL.h -1 .10 -6 hepatocytes (or cells); ke is the elimination rate constant expressed in h -1 calculated with
WinNonLin, via a compartmental analysis, modelling an intravenous bolus injection with no lag time (first order elimination); V is the incubation volume expressed in mL normalized to 10 6 hepatocytes). Elimination rate constants were determined over 24 h in the uninhibited (Ke) and inhibited (Kei) states. The relative CYP contribution to the overall Clint (fm %) was determined using the following equation:
Metabolic stability assay
The metabolic lability was evaluated at a concentration of 5 µM in mouse, rat and human compound by normalizing the data at different time point to T0 for analyte / internal standard peak area ratio: % stability = (peak area ratio at Tx / peak area ratio at T0); elimination slope (-k) was determined using a linear regression of the neperian logarithm (ln) of the percent remaining drug versus incubation time (k is expressed in µM / minute step from a -80mV holding potential to +20 mV for 5 s. Then, a second repolarizing step to -50 mV was applied for another 5 s, followed by return to holding at -80 mV. Cycle time was 15 s, recordings were performed at room temperature and drug effects were evaluated on the peak tail-current elicited by the second repolarizing step. For pharmacology, stock solutions of the test articles at 10 mM were prepared in DMSO and delivered frozen by Sanofi's internal compound management services. A 6-point concentration-range was prepared in polypropylene micro-titer plates in two steps by first serially diluting the initial 10 mM stock In vitro study of the trans-epithelial intestinal transport of VCC234718 using Caco-
2/TC-7 cell monolayers
The TC7 clone was established from the parental Caco-2 cell line, a human colon adeno- Tet-OFF configurations were cultured, and transcriptional silencing carried out, as previously described.
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Drug susceptibility testing
The Alamar Blue (AB) assay was used for MIC testing by broth microdilution, as described previously. [1] [2] The time-kill kinetics of Mtb H37Rv exposed to VCC234718 over a drug concentration range of 0-32 µM were assessed as previously described. 1 Serial dilutions of each sample were plated on 7H10 agar at days 0, 1, 2, 3, 5 and 7 and CFUs were scored following incubation at 37C for 3-4 weeks. The streptomycin-dependent Mtb 18b strain and its luminescent derivative, 18b-Lux, were used to assess the activity of VCC234178 against non-replicating bacilli, as previously described. [3] [4] The intracellular activity of VCC718 was assessed in MRC-5 fibroblasts and activated THP-1 macrophages by monitoring the ability of the compound to protect the cells from Mtb-induced lysis, as described by Rybniker et al. 
Construction of mutant strains of Mtb with altered expression of GuaB2
To construct Mtb strains carrying an integrated copy of guaB2 or guaB2 Y487C , the plasmids pTTguaB2 and pTTGuaB2 Y487C carrying guaB2 or guaB2 Y487C under control of the native promoter of the guaB2-guaB3 operon were constructed by PCR amplification of the 1920 bp region spanning the guaB2 ORF and 330 bp of upstream sequence using genomic DNA from H37Rv or the VCC234718-resistant strain, SRMV2.6, as template, and the primers listed in Table S5 . To construct Mtb strains carrying an integrated copy of the wild type guaB2-guaB3
operon, a 3086 bp region spanning the guaB2-guaB3 genes and 330 bp of upstream sequence was amplified using genomic DNA from H37Rv and the primers listed in Table S6 . The amplified products were digested with EcoRI and cloned in the Tweety-based integrating plasmid pTT1B::Gm. 2 The resulting plasmids, pTTguaB2, pTTguaB2 Y487C and pTTguaB2-guaB3 were electroporated individually into H37Rv or SRMV2.6 to produce the strains, with an in-frame deletion of the guaB2 gene, was performed by the splice-by-overlapextension method. 9 Briefly, a first-round of PCR amplification of fragments flanking guaB2 was performed using primers Rv3012c-EcoRI-For/ guaB2'-SOE-Rev, and guaB3-SOE-For/ guaB3-EcoRI-Rev (Table S5) . The amplicons, which contain overlapping extensions, were purified, combined and used as a template in a second-round PCR using the primers Rv3012c-EcoRI-For/ guaB3-EcoRI-Rev. The full-length PCR product was purified, restricted
with EcoRI, and cloned in pTT1B-Gm to produce pTTguaB3, which was integrated into guaB2-guaB3 Tet-OFF to produce the complemented mutant, guaB2-guaB3 Tet-OFF attB::guaB3.
Western blot analysis
Cultures of Mtb strains were grown to an OD600 of 0.5 in Middlebrook 7H9 broth supplemented with antibiotics, as required, treated with ATc (10 ng/mL) and incubated at 
Gene expression analysis by ddPCR
Total RNA from Mtb cultures was extracted using a FastRNA ProBlue Kit (MP Biomedicals), as per the manufacturer's instructions, followed by two rounds of DNase treatment of RNA using Turbo DNase (Ambion). DNase-treated RNA (100 ng) was used as template for cDNA synthesis using iScript TM cDNA synthesis kit (Bio-Rad). Primers and S11 TaqMan minor groove binder (MGB) probes (Table S5) were designed using Primer Express software (version 3.0.1). To facilitate the multiplexing of the assay, TaqMan MGB probes homologous to the target gene were labelled with 6-carboxyfluorescein (FAM) whereas the reference gene, sigA, was labelled with 4,7,2'-trichloro-7'-phenyl-6-carboxyfluorescein (VIC). The PCR was performed as described previously 1 cycling at 95C for 10 min; 40 cycles of 94C for 30 s and 60C for 60 s; and 98C for 10 min in a conventional T100
Thermal Cycler (Bio-Rad), after which the droplets were analysed using a QX200 Droplet
Reader (Bio-Rad). Three technical replicates of each gene were run for each biological replicate. The analysis was performed as described previously 1 .
Analysis of cidality caused by GuaB2 depletion in vitro
To test the guaB2 silencing effect on viability of bacteria, the guaB2-guaB3 Tet-OFF Cloning, expression and purification of wildtype and Y487C Mtb GuaB2 and Mth
GuaB2
The Rv3411c gene encoding Mtb GuaB2 was PCR amplified (Table S5) imidazole, then the bound His-tag N-terminal enzyme was eluted with Buffer A supplemented with 500 mM imidazole, and fractions containing Mtb GuaB2 were pooled and loaded on a HiPrep 26/10 desalting column with Buffer A. The resulting protein was collected and concentrated to 0.5 mg/mL. All the purification steps above described were performed at 4ºC. Concentrations were determined by Bradford assay, and sample purity was assessed by 10% SDS-PAGE.
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The construct coding for wildtype Mtb GuaB2, obtained as detailed above, was used as the DNA template in a PCR-based site-directed mutagenesis experiments, using the QuikChange II site directed mutagenesis kit reagents (Stratagene) and the primer pairs Y487C_forward 5'-gcgacccggtgcagcccatcgcg-3' and Y487C_reverse 5'-cgcgatgggctgcaccgggtcgc-3'. The region encoding the mutant Mtb GuaB2 variant in the resulting expression construct was verified by sequencing (Eurofins MWG Operon). The expression and purification of Mtb GuaB2 carrying the Y487C mutation was carried out using the same procedure as for the wildtype enzyme, as described above.
The gene encoding Mth GuaB2 was amplified from genomic DNA. In order to facilitate protein expression and crystallisation, the GuaB2 gene was cloned into the pHat2 vector after removing the 2 CBS domains and replacing with a GG linker connecting the two parts of the catalytic region (Mth GuaB2 ∆CBS). The pHat2 vector has an N-terminal His6-tag and a TEV site was included in the construct to enable affinity-tag removal. The Mth GuaB2 ∆CBS protein was expressed in BL21 DE3 (NEB) cells at 37°C until the OD600 reached 0.6, then expression was induced by reduction of the temperature to 18°C and addition of IPTG at a final concentration of 500 μM. Cells were left growing overnight; after which they were harvested by centrifugation, resuspended in 50 mM Hepes pH 8.0, 500 mM NaCl, 5% glycerol, 10 mM -mercaptoethanol, 20 mM imidazole and lysed by 3 passes through an Emulsiflex cell disruptor (Avastin). The resulting lysate was clarified by highspeed centrifugation and filtration through a 0.45 μm filter. This was then applied to a HiTrap IMAC FF column (GE Healthcare) charged with Nickel. The bound protein was eluted with lysis buffer + 250 mM imidazole. The elution fractions were pooled and dialysed overnight into lysis buffer -imidazole. In order to remove the N-terminal His-tag the protein was incubated with TEV protease during dialysis. A negative nickel gravity-flow purification step was performed to remove the uncleaved protein and the protease. The flow-through from S15 this step was concentrated and applied to a Superdex 200 gel filtration column preequilibrated with 20 mM Hepes pH 8.0, 500 mM NaCl, 5% glycerol, 1 mM TCEP. Elution fractions were collected and concentrated to 12.5 mg/mL for crystallisation.
Enzyme kinetics
Recombinant Mtb GuaB2 was prepared as described above and human IMPDH was purchased from Sigma-Aldrich. The enzymatic activity was measured by a continuous spectrophotometric assay 12 The apparent steady-state parameters for Mtb GuaB2 on its natural substrates were collected using the continuous spectrophotometric assay described previously 12 . IMP and NAD + concentrations when held constant were at 1.25 mM and 3 mM, respectively. The concentrations of IMP were varied from 0.01 mM to 0.6 mM, and for NAD + , were varied from 0.1 mM to 3 mM. Data points were obtained from three independent experiments. Kinetic parameters were calculated by using a nonlinear least square fit of the data using Sigma Plot-Enzyme Kinetics Module 1.3. IMP, and NAD + data were fitted with Equation 1
(the Michaelis-Menten equation for hyperbolic substrate kinetics).
v=Vmax x S/(KM+S) (Eq. 1)
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In which v, Vmax, S, and KM represent, respectively, steady state reaction rate (µmol min -1 mg -1 ), maximum reaction rate, substrate concentration, and Michaelis-Menten constant for S.
For the enzyme inhibition study, the concentration of VCC234718 required to reduce the fractional enzyme activity to half of its initial value in the absence of inhibitor (IC50) Table S3 . Steady-state kinetic parameters for Mtb GuaB2 and inhibition constant (Ki) for VCC234718, determined as described under Methods. Images were recorded on phase. Numbers (top left) indicate time elapsed. Labels (top right) indicate the medium supplements. Scale bar (5 m) is indicated on bottom left. Snapshots at some time points which were out-of-focus were removed when assembling the movie. Movie S1 is a representative movie where none of the surviving cells recover growth on ATc withdrawal, whereas Movie S2 is a representative example, where some of the survivors were able to grow and divide on guanine supplementation.
